Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B

Hepatitis B virus (HBV) chronically infects around 250 million individuals worldwide and can cause liver cirrhosis as well as hepatocellular carcinoma (HCC) [1]. The treatment options for chronic hepatitis B (CHB) are either pegylated interferon-alfa (PEG-IFN α) or nucleos(t)ide analogues (NA). PEG-IFNα has the advantage of finite treatment with higher rates of anti-HBs seroconversion of around 10%, but is associated with considerable side effects [2]. Thus, well-tolerated NAs are most commonly used.

Source: Journal of Hepatology - May 11, 2018 Category: Gastroenterology Authors: Franziska Rinker, Christine L. Zimmer, Christoph H öner zu Siederdissen, Michael P. Manns, Anke R.M. Kraft, Heiner Wedemeyer, Niklas K. Björkström, Markus Cornberg Source Type: research